Brief: Solid Biosciences Receives FDA Orphan Drug Designation For Sgt-212 Dual-Route Gene Therapy
12/01/2026 21:16
Jan 12 (Reuters) - Solid Biosciences Inc SLDB.O: SOLID BIOSCIENCES RECEIVES FDA ORPHAN DRUG DESIGNATION FOR SGT-212 DUAL-ROUTE GENE THERAPY FOR THE TREATMENT OF FRIEDREICH’S ATAXIA SOLID BIOSCIENCES- DOSING OF FIRST PARTICIPANT IN PHASE 1B FALCON TRIAL COMPLETED, INITIAL DATA EXPECTED IN H2 2026 Source text: ID:nGNXbmM6G5 Further company coverage: SLDB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Solid Biosciences
See all newsSolid Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Solid Biosciences Inc expected to post a loss of 48 cents a share - Earnings Preview
Solid Biosciences Q2 net loss widens on higher R&D costs
Marketing Agreement To Advance Gene Therapy Delivery And Analytics
Solid Biosciences Q1 net loss widens on higher R&D costs